Jubilant Pharmova plans non-convertible debentures (NCDs)
Jubilant Pharmova (JUBLPHARMA) said it has taken up non-convertible debentures (NCDs). The company is valued at about ₹14,843 crore.
What happened
In a filing with the BSE on 12 October 2026 at 12:35 PM, Jubilant Pharmova (JUBLPHARMA) said that it has taken up non-convertible debentures (NCDs).
Company snapshot
Jubilant Pharmova is a small-cap company in the Healthcare sector, with a market value of about ₹14,843 crore.
The stock last traded at ₹931.9, against a 52-week range of ₹786.1–₹1,184.8 (21.4% below the high).
Before this filing the shares had moved −8.6% over the month and −4.2% over three months. Average daily turnover over the last 20 sessions was about ₹24.63 crore.
Promoters held 47.68% at the end of Q1 FY27; 6.58% of promoter shares were pledged. Foreign institutions owned 15.87% and domestic institutions 12.40%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,901 | 102.9 | 6.49 |
| Q2 FY26 | 1,966 | 120.3 | 7.59 |
| Q3 FY26 | 2,123 | 55.9 | 3.52 |
| Q4 FY26 | 2,290 | 119.4 | 7.55 |
| Q1 FY27 | 2,229 | 56.5 | 3.57 |
What history shows
BCEIE has no earlier fund raising filing from this company on record since May 2026.
Across 27 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +1.0% over five days; 52% of them rose the next day.
Market-wide, 1,553 fund raising filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 48% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- How the money raised is used and, for equity instruments, the dilution for existing shareholders.
- 12 October 2026: Board meeting — Fund Raising.
In the news
Recent coverage elsewhere (links open the original publisher):
- Jubilant Pharmova Announces CAD 94.5 Million Investment To Double Ruby-Fill Production Capacity
- Jubilant Pharmova radiopharma unit to invest CAD 94.5 million to double RUBY-FILL production
- Jubilant Pharmova radiopharma unit to invest CAD 94.5 million to double RUBY-FILL production - CNBC TV18
- Jubilant Pharmova Ltd Surges 10.47%
- Jubilant Pharmova To Consider Raising Of Funds Through Issuance Of Non- Convertible Debentures
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.